Consensus Gilead Sciences, Inc. CBOE

Stocks

US3755581036

Pharmaceuticals

Market Closed - CBOE 18:30:00 21/09/2026 +03			After hours 19:45:56
131.66 ^EUR	+2.36%		131.59	-0.05%

09-18	Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2%	MT
09-16	Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing	MT

876.AnOOcIZFDIfoQs26xjGQ9orY8vsAg-fY9opOl6WC8Pw.NTv-M_Y8WtCSE_6DsXzoh_-vt5xEtITpweF93_HWpKl7A9Y9tRBO0t04-Q~547c3a1ec25ea51c1ae380456ce67934

Analysts' recommendations: Gilead Sciences, Inc.

09-10	HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating	MT
08-05	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says	MT
08-05	Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126	MT
08-05	Goldman Sachs Adjusts Price Target on Gilead Sciences to $135 From $130	MT
08-05	RBC Capital Adjusts Gilead Sciences Price Target to $123 From $120, Maintains Sector Perform Rating	MT
08-04	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says	MT
07-28	Barclays Adjusts Gilead Sciences Price Target to $145 From $155, Maintains Equalweight Rating	MT
07-23	Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating	MT
07-21	Gilead Sciences Shares Fall After Downgrade From Leerink Partners	MT
07-21	Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
07-21	Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146	MT
07-08	Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says	MT
07-08	Morgan Stanley Adjusts Price Target Gilead Sciences to $166 From $168, Maintains Overweight Rating	MT
07-07	Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157	MT
07-07	RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating	MT
07-06	Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
07-06	HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133	MT
06-08	Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says	MT
05-20	Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165	MT
05-19	Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating	MT
05-11	Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says	MT
05-11	Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170	MT
05-08	Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148	MT
05-08	Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says	MT
05-08	Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175	MT

More recommendations

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
GILEAD SCIENCES, INC.	-	-	-	-
ELI LILLY AND COMPANY				+14.96%
JOHNSON & JOHNSON				+2.93%
ABBVIE INC.				+5.55%
ROCHE HOLDING AG				+5.2%
NOVARTIS AG				+9.33%
ASTRAZENECA PLC				+26.44%
AMGEN INC.				+0.53%
NOVO NORDISK A/S				+10.16%
GILEAD SCIENCES, INC.				+5.35%
Average				+8.94%
Weighted average by Cap.				+9.45%